Kymera Therapeutics, Inc. (NASDAQ:KYMR) director Bruce Booth has been involved in a significant divestiture of company stock. On June 29, 2026, Booth facilitated the sale of common stock valued at approximately $3.42 million. The transaction encompassed a total of 31,283 shares, with execution prices varying between $108.28 and $111.20 per share. These sales were conducted under the parameters of a Rule 10b5-1 trading plan, which was established by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
The timing of this sale is particularly noteworthy given the recent performance of KYMR shares. Over the past year, the stock has surged by 150% and is currently trading at $114.69. According to InvestingPro data, the stock’s Relative Strength Index (RSI) indicates that it is in overbought territory. Furthermore, InvestingPro analysis suggests that the stock is overvalued relative to its Fair Value, with 16 additional ProTips available to subscribers.
The shares were held indirectly through two entities: Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. Specifically, Atlas Venture Fund X, L.P. sold 27,000 shares, while Atlas Venture Opportunity Fund I, L.P. sold 4,283 shares. The prices reported for these transactions are weighted averages, reflecting multiple sales at varying prices within specific ranges. For instance, some shares were sold at prices ranging from $108.0326 to $109.019, while others ranged from $111.09 to $111.63.
Mr. Booth is a member of the general partners of both Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. He disclaims beneficial ownership of the securities held by these funds, except to the extent of any pecuniary interest he may have. Following these transactions, Atlas Venture Fund X, L.P. holds 2,385,747 shares, and Atlas Venture Opportunity Fund I, L.P. holds 461,794 shares.
In other recent developments, Kymera Therapeutics has completed enrollment in its Phase 2b BROADEN2 trial for KT-621, an oral STAT6 degrader targeting moderate to severe atopic dermatitis. This enrollment was completed nearly six months ahead of schedule. The accelerated timeline allows the company to anticipate a topline data release by year-end 2026, earlier than the initially projected mid-2027. Following this development, several firms have adjusted their price targets for Kymera Therapeutics. Truist Securities increased its price target to $136, citing the expedited trial timeline and recent biotech mergers and acquisitions. Canaccord Genuity raised its target to $129, maintaining a Buy rating, following the trial’s rapid progress. B.Riley also raised its price target to $155, noting the early completion of enrollment and the subsequent shift in the expected data release. These adjustments reflect confidence in the company’s progress and potential future developments in its drug pipeline.